diquafosol diquafosol diquafosol (tradename diquas) is a pharmaceutical drug for the treatment of dry eye disease. it was approved for use in japan in 2010. it is formulated as a 3% ophthalmic solution of the tetrasodium salt. diquafosol names iupac name o1,o7-di(5′-deoxyuridin-5′-yl) tetrahydrogen tetraphosphate systematic iupac name o1,o7-bis tetrahydrogen tetraphosphate other names p1,p4-bis(5'-uridyl) tetraphosphate; ins-365; diquafosol tetrasodium identifiers cas number 59985-21-6 y211427-08-6 (tetrasodium salt) y 3d model (jsmol) interactive image chembl chembl1767408chembl221326 chemspider 130647130646 (tetrasodium salt) iuphar/bps 1736 pubchem cid 148197148196 (tetrasodium salt) unii 7828vc80fj yx8t9sbh9ll (tetrasodium salt) y comptox dashboard (epa) dtxsid40208689 inchi inchi=1s/c18h26n4o23p4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28h,5-6h2,(h,31,32)(h,33,34)(h,35,36)(h,37,38)(h,19,23,29)(h,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1key: nmlmacjwhphkgr-ncoidobvsa-ninchi=1/c18h26n4o23p4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28h,5-6h2,(h,31,32)(h,33,34)(h,35,36)(h,37,38)(h,19,23,29)(h,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1key: nmlmacjwhphkgr-ncoidobvbd smiles o=c1\c=c/n(c(=o)n1)2o((o)2o)cop(=o)(o)op(=o)(o)op(=o)(o)op(=o)(o)oc4o(n\3c(=o)nc(=o)/c=c/3)(o)4o properties chemical formula c18h26n4o23p4 molar mass 790.306 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). infobox references its mechanism of action involves agonism of the p2y2 purinogenic receptor.